[go: up one dir, main page]

HN2012001413A - Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos - Google Patents

Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos

Info

Publication number
HN2012001413A
HN2012001413A HN2012001413A HN2012001413A HN2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A HN 2012001413 A HN2012001413 A HN 2012001413A
Authority
HN
Honduras
Prior art keywords
treatment
neurological disorders
pirazine
derivatives
pirazine derivatives
Prior art date
Application number
HN2012001413A
Other languages
English (en)
Inventor
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2012001413(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2012001413A publication Critical patent/HN2012001413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A NOVEDOSOS COMPUESTOS HETEROCÍCLICOS DE LA FÓRMULA (I) EN DONDE TODAS LAS VARIABLES SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA, EN FORMA LIBRE ON EN FORMA DE SAL, A SU PREPARACIÓN A SU USO MÉDICO, Y A MEDICAMENTOS QUE LOS COMPRENDEN.
HN2012001413A 2009-12-31 2012-06-28 Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos HN2012001413A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31

Publications (1)

Publication Number Publication Date
HN2012001413A true HN2012001413A (es) 2015-03-23

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012001413A HN2012001413A (es) 2009-12-31 2012-06-28 Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos

Country Status (27)

Country Link
US (2) US20120277244A1 (es)
EP (1) EP2519515B1 (es)
JP (1) JP5600754B2 (es)
KR (1) KR101419157B1 (es)
CN (1) CN102712621B (es)
AU (1) AU2010338365B2 (es)
BR (1) BR112012015916A2 (es)
CA (1) CA2785341A1 (es)
CL (1) CL2012001762A1 (es)
CR (1) CR20120332A (es)
CU (1) CU20120099A7 (es)
EA (1) EA201200952A1 (es)
EC (1) ECSP12012065A (es)
ES (1) ES2445536T3 (es)
GT (1) GT201200219A (es)
HN (1) HN2012001413A (es)
IL (1) IL220268A0 (es)
MX (1) MX2012007754A (es)
NZ (1) NZ600136A (es)
PE (1) PE20121640A1 (es)
PH (1) PH12012501007A1 (es)
PL (1) PL2519515T3 (es)
PT (1) PT2519515E (es)
SG (1) SG181431A1 (es)
TN (1) TN2012000249A1 (es)
WO (1) WO2011080176A1 (es)
ZA (1) ZA201203614B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006307314C1 (en) 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
EA020740B1 (ru) 2008-06-13 2015-01-30 Шионоги & Ко., Лтд. Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
TWI488852B (zh) 2009-12-11 2015-06-21 Shionogi & Co 衍生物
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
WO2011154431A1 (en) 2010-06-09 2011-12-15 Janssen Pharmaceutica Nv 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP2013529664A (ja) * 2010-06-28 2013-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アルツハイマー病および他の型の認知症の処置に有用な３−アミノ−５，６−ジヒドロ−１ｈ−ピラジン−２−オン誘導体
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
MY170715A (en) 2010-12-22 2019-08-27 Janssen Pharmaceutica Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
CN106117193B (zh) 2011-01-13 2019-09-13 诺华股份有限公司 新的杂环衍生物及其在神经性疾病治疗中的应用
KR20140010031A (ko) * 2011-01-13 2014-01-23 노파르티스 아게 대사 장애의 치료를 위한 ｂａｃｅ-2 억제제
HUE026338T2 (en) 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
JP5853035B2 (ja) 2011-03-09 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
CA2832473A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions, and their use
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
CN105452251B (zh) 2013-06-12 2017-12-26 詹森药业有限公司 作为β‑分泌酶(BACE)抑制剂的4‑氨基‑6‑苯基‑5,6‑二氢咪唑并[1,5‑A]吡嗪‑3(2H)‑酮衍生物
WO2014198853A1 (en) 2013-06-12 2014-12-18 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
CA2911693C (en) 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
WO2016096979A1 (en) 2014-12-18 2016-06-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
AU2006307314C1 (en) * 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
PL2404919T3 (pl) * 2005-11-08 2014-01-31 Vertex Pharma Związek heterocykliczny użyteczny jako modulator transporterów zawierających kasetę wiążącą ATP
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
MY160690A (en) 2008-01-18 2017-03-15 Eisai R&D Man Co Ltd Condensed aminodihydrothiazine derivative
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
JP2013529664A (ja) * 2010-06-28 2013-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アルツハイマー病および他の型の認知症の処置に有用な３−アミノ−５，６−ジヒドロ−１ｈ−ピラジン−２−オン誘導体

Also Published As

Publication number Publication date
KR20120102795A (ko) 2012-09-18
TN2012000249A1 (en) 2013-12-12
CN102712621A (zh) 2012-10-03
PT2519515E (pt) 2014-02-17
BR112012015916A2 (pt) 2017-04-25
ZA201203614B (en) 2013-01-30
NZ600136A (en) 2013-09-27
AU2010338365B2 (en) 2014-01-30
IL220268A0 (en) 2012-07-31
US20120277244A1 (en) 2012-11-01
ECSP12012065A (es) 2012-08-31
KR101419157B1 (ko) 2014-07-11
PE20121640A1 (es) 2012-12-17
CN102712621B (zh) 2015-03-11
CL2012001762A1 (es) 2012-12-21
US20150322038A1 (en) 2015-11-12
MX2012007754A (es) 2012-08-01
WO2011080176A1 (en) 2011-07-07
SG181431A1 (en) 2012-07-30
GT201200219A (es) 2013-10-10
HK1172023A1 (en) 2013-04-12
CU20120099A7 (es) 2012-07-31
EP2519515A1 (en) 2012-11-07
CA2785341A1 (en) 2011-07-07
ES2445536T3 (es) 2014-03-03
EP2519515B1 (en) 2013-11-06
PL2519515T3 (pl) 2014-04-30
EA201200952A1 (ru) 2013-02-28
AU2010338365A1 (en) 2012-06-07
CR20120332A (es) 2012-07-12
JP5600754B2 (ja) 2014-10-01
PH12012501007A1 (en) 2013-01-14
JP2013516395A (ja) 2013-05-13

Similar Documents

Publication Publication Date Title
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
UY32799A (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
UY33883A (es) Novedosos derivados heterocíclicos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY33458A (es) Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
UY32404A (es) 4-aril-butan-1,3-diamidas
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY32748A (es) 2-carboxamida-cicloamino-ureas
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
UY33180A (es) Derivados de ácido carboxílico heterocíclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida.